Exhibit 99.2

Initial Data from Phase 1 ELiPSE-1 Trial of CNTY-101 in Relapsed/Refractory B-cell Lymphomas and Overview of Planned Phase 1 Study in Systemic Lupus Erythematosus December 11, 2023

2 Forward-looking statements This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbour provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this document, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding possible or assumed future results of operations, business strategies, research and development plans, regulatory activities, market opportunity, competitive position and potential growth opportunities are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this presentation are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this presentation and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control, including, among others: our ability to successfully advance our current and future product candidates through development activities, preclinical studies, and clinical trials; our dependence on the success of our lead product candidate, CNTY-101; the ability of CNTY-101 to be administered as part of a multi-dose strategy and to enable responses without lymphodepletion; uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials, which may not be predictive of final results or the results of later-stage clinical trials; the timing of and our ability to initiate and successfully enroll the Phase 1 SLE trial; our ability to obtain FDA clearance of our future IND submissions and commence and complete clinical trials on expected timelines, or at all; our reliance on the maintenance on certain key collaborative relationships for the manufacturing and development of our product candidates; the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product candidates; the impact of, geopolitical issues and inflation on our business and operations, supply chain and labor force; the performance of third parties in connection with the development of our product candidates, including third parties conducting our future clinical trials as well as third-party suppliers and manufacturers; our ability to successfully commercialize our product candidates and develop sales and marketing capabilities, if our product candidates are approved; and our ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the “Risk Factors” section of our most recent filings with the Securities and Exchange Commission and available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

3 Today’s agenda • Introduction Brent Pfeiffenberger, Pharm.D., Chief Executive Officer • Overview of Foundational Platform Technologies Hy Levitsky, M.D., President of Research and Development • Review of Initial ELiPSE-1 Data for CNTY-101 Nick Trede, M.D., Ph.D., SVP, Head of Clinical Development • CNTY-101 in Systemic Lupus Erythematosus Adrienne Farid, Ph.D., Chief Operations Officer and Head of Early Development • Closing Brent Pfeiffenberger, Pharm.D., Chief Executive Officer • Also Joining for Q&A Michael Diem, M.D., Chief Financial Officer Greg Russotti, Ph.D., Chief Technology and Manufacturing Officer

4 Century Therapeutics: Building an industry-leading, next-generation allogeneic iPSC-derived cell therapy platform LIMITLESS POTENTIAL... PRECISION DESIGN... ENDURING IMPACT... Foundational investments in iPSC technology, genetic editing, and manufacturing Progressing multiple clinical programs in oncology and autoimmune and inflammatory diseases Well-capitalized into 2026 to enable delivery on key milestones and clinical data

Overview of Foundational Platform Technologies: iPSCs, Allo-EvasionTM and the Creation of CNTY-101

6 Versatility and unprecedented control: Century’s next-generation allogeneic iPSC technology platform Iterative optimization of product functionality and manufacturability • Consistency • Yield • Fitness: No exhaustion Product design Manufacturing iPSC iT cell iNK cell Engineered iPSC MCB SINGLE CELL CLONING POST GENE EDITING AND CHARACTERIZATION DIFFERENTIATION • Allo-EvasionTM • Homeostasis/ persistence • Modulation of TME • Safety switch

7 Allo-EvasionTM 1.0 designed to overcome 3 major pathways of host vs. graft rejection 1. Deletion of β2M, a protein required to express HLA-1 on the cell surface prevents recognition by CD8 T cells 2. Knock out of CIITA eliminates HLA-II expression to escape elimination by CD4 T cells 3. Knock-in of HLA-E prevents killing by NK cells 2M KO (HLA-I) HLA-E KI CIITA KO (HLA-II) CD8+ T Cell CD4+ T Cell NK cell Three core edits disarm host cells from eliminating therapy CD19 CAR Safety Switch IL-15

8 CNTY-101: Differentiated next-gen CD19 targeted product 2M KO (HLA-I) HLA-E KI CIITA KO (HLA-II) CD8+ T Cell CD4+ T Cell NK cell CD19 CAR Safety Switch IL-15 • Goal to improve durability, tolerability and ease of outpatient administration • Potential to eliminate need for lymphodepletion with subsequent cycles of therapy • First CD19-targeted agent to test durability benefit of repeat dosing enabled by Allo-Evasion™ edits Delivering on our vision to change the cell therapy treatment paradigm

9 CNTY-101: Extending drug exposure in R/R B-cell NHL via repeat dosing and changing the treatment paradigm with Allo-EvasionTM R/R: relapsed or refractory, NHL: non-Hodgkin lymphoma, CAR-T: chimeric antigen receptor T cell therapy Potential solution from Century’s platform: • Off-the-shelf product offers immediate access and consistency • Multiple doses to increase pharmacological pressure to increase durability • Host rejection addressed by Allo-EvasionTM edits Unmet need: • Autologous CD19 CAR-T curative in only a subset of patients • Autologous CD19 CAR-T access is limited and/or can fail in manufacturing as quality is dependent on patient-derived starting material • Limited options and poor prognosis for patients who fail autologous CAR-T Aim: extending the period of pharmacologic pressure on tumor cells

Review of Initial ELiPSE-1 Data for CNTY-101

11 CNTY-101: ELiPSE-1 (NCT05336409) Phase 1 BOIN design 1 Standard lymphodepletion regimen: fludarabine (30 mg/m2/d) and cyclophosphamide IV (300 mg/m2/d) for 3 days 2Subjects who are assessed as stable disease or better may receive additional cycles of CNTY-101 BOIN: Bayesian Optimal Interval, DLBCL: diffuse large B cell lymphoma, tFL: transformed follicular lymphoma, PMBCL: primary mediastinal B-cell lymphoma, MCL: mantle cell lymphoma, FL3B: follicular lymphoma grade 3B, DLT: dose-limiting toxicity, RP2R: recommended Phase 2 regimen, ORR: objective response rate, CRR: complete response rate, DoR: duration of response, PK: pharmacokinetics, IL-2: interleukin-2 Initial Dose Additional Cycles2 First additional cycle: lymphodepletion at investigator’s discretion No lymphodepletion for following cycles Schedule A • Dose level 1: 100e6 • Dose level 2: 300e6 • Dose level 3: 1000e6LYMPHO-DEPLETION1 IL-2 x 22 days Schedule B • Dose level 2: 300e6 • Dose level 3: 1000e6 28-DAY DLT PERIOD RESPONSE ASSESSMENT Patient enrollment N=15 dose esc N=20 expansion CNTY-101 DAY 1 DAY 1 DAY 8 DAY 15 IL-2 x 8 days CNTY-101 CNTY-101 CNTY-101 IL-2 x 22 days CNTY-101 DAY 1 DAY 1 DAY 8 DAY 15 IL-2 x 8 days CNTY-101 CNTY-101 CNTY-101 Inclusion: • R/R CD19+ NHL • Aggressive B cell lymphoma (DLBCL, tFL, high-grade B cell lymphoma, PMBCL, MCL, FL3B) • High-risk indolent lymphoma Endpoints: • Primary: MTD based on DLTs; RP2R • Key Secondary: Safety, tolerability, Efficacy (ORR, CRR, DoR), PK • Exploratory: feasibility of additional cycles, Allo-EvasionTM

12 ELiPSE-1 initial data: Key takeaways • Heavily pretreated and refractory patient population treated in first-in-human dose escalation trial • Favorable safety profile; can be delivered in an outpatient setting • Encouraging early efficacy signals at lowest dose levels o 2 patients achieving CR, including 1 patient with 6-month durable CR • No evidence of allo-rejection • Initial data for CNTY-101 supports the potential for Allo-Evasion™ to enable a multi-dosing regimen without the need for continued lymphodepletion CR: Complete response

13 BASELINE CHARACTERISTICS Patients treated 7 Median age (range) 68 (60-72) PRIOR THERAPY Median # of prior therapies (range) 4 (2-6) Prior CD-19-targeted CAR T-cell therapy 3 a (43%) DISEASE CHARACTERISTICS Aggressive histology 5 (71%) Refractory to last line of therapy 6 (86%) Elevated LDH at screening 5 (71%) Stage 4 (Dx | Screening) 5 (71%) | 7 (100%) Median baseline target lesion SPD (mm2 ) (range) 2044 (641-29716) Data cutoff date of November 13, 2023; represents data verified post data cut a. One additional subject had CAR T-cell manufacturing failure LDH: Lactate dehydrogenase, SPD: sum of the products of diameters ELiPSE-1 enrolled heavily pretreated patients

14 COHORT PATIENT DISEASE HISTORY TREATMENT Indication Prior Lines Therapy Prior CAR T? Relapse or Refractory to Last Line Dose Cycles Completed DOSE LEVEL 1 1 iFL 4 N Refractory 100 x 106 7 2 DLBCL/tFL 4 Y Refractory 100 x 106 1 3 DLBCL 2 Na Refractory 100 x 106 1 4 DLBCL/tMZL 4 N Refractory 100 x 106 1 DOSE LEVEL 2 5 MZL 4 N Refractory 300 x 106 2 6 DLBCL 4 Y Refractory 300 x 106 1 7 DLBCL/tFL 6 Y Relapsed 300 x 106 1* Data cutoff date of November 13, 2023; represents data verified post data cut a. CAR T manufacturing failure CRS: cytokine release syndrome, ICANS: immune effector cell–associated neurotoxicity syndrome, AE: adverse event, SAE: serious adverse event ELiPSE-1: Overview of patients

15 COHORT PATIENT DISEASE HISTORY TREATMENT SAFETY Indication Prior Lines Therapy Prior CAR T? Relapse or Refractory to Last Line Dose Cycles Completed DLTs CRS (Grade) ICANS CNTY-101 Related Gr3+ AE/SAE DOSE LEVEL 1 1 iFL 4 N Refractory 100 x 106 7 N N N N 2 DLBCL/ tFL 4 Y Refractory 100 x 106 1 N N N N 3 DLBCL 2 Na Refractory 100 x 106 1 N N N N 4 DLBCL/ tMZL 4 N Refractory 100 x 106 1 N Y (1) N Y DOSE LEVEL 2 5 MZL 4 N Refractory 300 x 106 2 N Y (2) N Y 6 DLBCL 4 Y Refractory 300 x 106 1 N N N N 7 DLBCL/ tFL 6 Y Relapsed 300 x 106 1* N* N* N* N* *Data cutoff date of November 13, 2023; represents data verified post data cut a. CAR T manufacturing failure ELiPSE-1: Favorable initial safety profile

16 ELiPSE-1: Early evidence of anti-lymphoma activity at lowest dose levels COHORT PATIENT DISEASE HISTORY TREATMENT SAFETY RESPONSE Indication Prior Lines The rapy Prior CAR T? Relapse or Refractory to Last Line Dose Cycles Completed DLTs CRS ICANS CNTY-101 Related Gr3+ AE/SAE Best Overall Response DOSE LEVEL 1 1 iFL 4 N Refractory 100 x 106 7 N N N N CR 2 DLBCL/tFL 4 Y Refractory 100 x 106 1 N N N N PD 3 DLBCL 2 N a Refractory 100 x 106 1 N N N N PD 4 DLBCL/tMZL 4 N Refractory 100 x 106 1 N Y N Y PD DOSE LEVEL 2 5 MZL 4 N Refractory 300 x 106 2 N Y N Y PR 6 DLBCL 4 Y Refractory 300 x 106 1 N N N N PD 7 DLBCL/tFL 6 Y Relapsed 300 x 106 1* N* N* N* N* CR* *Data cutoff date of November 13, 2023; represents data verified post data cut a. CAR T manufacturing failure

17 Initial Dose lympho-depletion No IL-2 Sex/Age: Female/63 Tumor Subtype: Follicular Lymphoma Dose/Schedule: 100e6 cells x 1 per cycle (Dose Level 1; Schedule A) Prior Therapy: • 4 prior lines of therapy including anti-CD20, bispecific, and investigational therapy • High-risk R/R - Relapsed within 12 months of starting R-CHOP Additional Cycle 1 lympho-depletion IL-2 Additional Cycle 2 IL-2 Additional Cycle 3 IL-2 Additional Cycle 4 IL-2 Additional Cycle 5 IL-2 Additional Cycle 6 IL-2 *Data cutoff date of November 13, 2023; represents data verified post data cut Patient subsequently progressed Ramachandran, et al. 2023 ASH Annual Conference IL-2: subcutaneous 3e6 IU for 8 days, except for initial cycle No lymphodepletion Multiple Doses of CNTY-101, an iPSC-Derived Allogeneic CD19 Targeting CAR-NK Product, are Safe and Result in Tumor Microenvironment Changes Associated with Response: A Case Study Indu Ramachandran1 , Sarah Rothman1 , Mariano Clausi1 , Kile McFadden1 , Brenda Salantes1 , Gloria Jih1 , Thomas Brigman1 , Sam Kelly1 , Matthew S. Hall1 , Stephanie Yee1 , Iphigenia Koumenis1 , Poulomee Das1 , Jordan Briggs2 , Tori Braun2 , Ying Yuan3 , Elizabeth Devlin1 , Adrienne Farid1 , Nikolaus Trede1 , Tamara K. Moyo5 , Tahir Latif4, Krish Patel2 1Century Therapeutics, Philadelphia, PA 2Swedish Cancer Institute, Seattle, WA 3MD Anderson Cancer Center, Houston, TX 4Atrium Health Levine Cancer Institute, Charlotte, NC 5University of Cincinnati Medical Center, Cincinnati, OH ASH case study: Dose level 1 patient with 6-month durable complete response

18 *Data cutoff date of November 13, 2023; represents data verified post data cut AC: Additional Cycle Ramachandran, et al. 2023 ASH Annual Conference ASH case study: Favorable initial safety profile With LD No LD Safety profile​ in first 7 subjects: • No DLTs, no CRS, no ICANS​ • No AEs related to CNTY-101​ • Factors associated with CRS and neurotoxicity were not significantly elevated​ • Elevation in peripheral IL-2 is observed, coinciding with IL-2 administration

19 Patient subsequently progressed Ramachandran, et al. 2023 ASH Annual Conference ASH case study: Early evidence of anti-lymphoma activity with durable 6-month complete response Baseline Post-initial dose (Day 28)

20 ASH case study: CNTY-101 persists outside of circulation and humoral immunogenicity is not detected cfDNA: cell-free DNA, LD: lymphodepletion Ramachandran, et al. 2023 ASH Annual Conference PK shows CNTY-101 cells traffic out of circulation shortly after infusion; consistent levels at 1 hour post-infusion are observed with and without LD Detectable signal [+] was determined to be significantly above negative controls using two sample Poisson test, p < 0.05; transgene copies detected in 1 mL of plasma is indicated CNTY-101 cells persist in tissues for at least three days as measured by cfDNA; consistent CNTY-101 cfDNA levels are observed with and without LD at Day 3. With LD No LD Anti-drug antibodies and functional humoral immune response against CNTY-101 are not detected (five cycles evaluated). ADCC CDC

21 ASH case study: Intra-tumoral adaptive immune response observed following initial dose without IL-2 CD8Ki67 CD8Ki67 CD56Ki67 CD56Ki67 CARTNFAIFNG CARTNFAIFNG Total Ki67+ TNF-α IFN-γ Total Ki67+ 0 200 400 600 800 1000 Cells per mm2 CD8+ T cells Endogenous NK cells Secreting cells SCREEN DAY 8

22 Summary of ELiPSE-1 data • Heavily pretreated and refractory patient population treated in first-in-human dose escalation trial • Favorable safety profile; can be delivered in an outpatient setting • Encouraging early efficacy signals at lowest dose levels o 2 patients achieving CR, including 1 patient with 6-month durable CR • No evidence of allo-rejection • Initial data for CNTY-101 supports the potential for Allo-Evasion™ to enable a multi-dosing regimen without the need for continued lymphodepletion • We believe CNTY-101’s manageable initial safety profile, initial response data, and PK/PD supports advancing to higher doses to potentially deepen and prolong clinical response Cohorts of 1 billion cells/1 monthly dose and 300 million/weekly x 3 doses are open;​ Additional clinical data expected in mid-2024

CNTY-101 in Systemic Lupus Erythematosus

24 Estimated global prevalence of 3.4 million patients1 • Abnormal B cell function and autoantibody production are central to disease pathogenesis • Major causes of morbidity and mortality involve multiple systems o Renal, CNS and cardiovascular involvement are major causes of morbidity and mortality Despite approved treatments, significant unmet need remains • Chronic treatment with broad-acting anti-inflammatory and immunosuppressives • Current treatments fail to significantly impact morbidity in the moderate to severe population • Treatment toxicity and disease flares remain common Autologous anti-CD19 CAR T cell therapies have established a promising efficacy proof of concept in SLE2 • Challenges remain due to potential exposure to CRS and ICANS, product availability, and long-term risks including B-cell aplasia Opportunity in systemic lupus erythematosus to improve long-term disease control 1. Tian J, et al. Ann Rheum Dis 2023;82:351–356 http://dx.doi.org/10.1136/ard-2022-223035 2. Mackensen A, et al.. Nature Medicine 2022 28:10 (2124-2132) https://doi.org/10.1038/s41591-022-02017-5 CNS: central nervous system, SLE: systemic lupus erythematosus

25 CNTY-101 aims to eliminate pathogenic B-cells in SLE leading to remission via repeat dosing facilitated by Allo-EvasionTM CNTY-101 has the potential to improve on current SLE treatments • Anti-CD19 CAR-iNK cells derived from an HDR precision-edited iPSC clone, including IL-15 cytokine support, a safety switch, and Allo-EvasionTM edits • Clonal, consistent, well-characterized product • Available off-the-shelf, without requiring patient apheresis, no manufacturing wait time • Favorable initial safety profile, allowing for outpatient treatment • Ability to be redosed without lymphodepletion, while avoiding allo-rejection based on initial data • Potential to enable B cell depletion and a reduction in auto-antibodies without prolonged B-cell aplasia Aim: Safely provide immune reset with an immediately available therapy HDR: homology-directed repair

26 Isolated B cells or CD19+ target cells were co-cultured with CNTY-101 or primary CAR-T at several E:Ts in 96-well U bottom plates in NKCM with assay harvested at 24h. Assay plates were harvested and stained for Fixable Live/Dead. Cells were fixed and run on cytometer to determine Target+Dead Cell populations. 16:1 8:1 4:1 2:1 1:1 1:2 1:4 1:8 1:16 Target Alone 0 20 40 60 80 Healthy Donor 1 % Cytolysis (CTV- Dead Cells) E:T % Cytolysis (%Dead on CTV- Target Cells) CNTY-101 CAR-T (Donor 1) UTD (Donor 1) 16:1 8:1 4:1 2:1 1:1 1:2 1:4 1:8 1:16 Target Alone 0 20 40 60 80 100 Healthy Donor 2 % Cytolysis (CTV- Dead Cells) E:T % Cytolysis (%Dead on CTV- Target Cells) CNTY-101 CAR-T (Donor 2) UTD (Donor 2) 16:1 8:1 4:1 2:1 1:1 1:2 1:4 1:8 1:16 Target Alone 0 20 40 60 80 Healthy Donor 3 % Cytolysis (CTV- Dead Cells) E:T % Cytolysis (%Dead on CTV- Target Cells) CNTY-101 CAR-T (Donor 3) UTD (Donor 3) 16:1 8:1 4:1 2:1 1:1 1:2 1:4 1:8 1:16 Target Alone 0 20 40 60 80 SLE Donor 1 % Cytolysis (CTV- Dead Cells) E:T % Cytolysis (%Dead on CTV- Target Cells) 16:1 8:1 4:1 2:1 1:1 1:2 1:4 1:8 1:16 Target Alone 0 20 40 60 80 SLE Donor 2 % Cytolysis (CTV- Dead Cells) E:T % Cytolysis (%Dead on CTV- Target Cells) 16:1 8:1 4:1 2:1 1:1 1:2 1:4 1:8 1:16 Target Alone 0 20 40 60 80 SLE Donor 3% Cytolysis (CTV- Dead Cells) E:T % Cytolysis (%Dead on CTV- Target Cells) CNTY-101 CAR-T (from Healthy Donor 1) CAR-T (from Healthy Donor 2) CAR-T (from Healthy Donor 3) UTD (from Healthy Donor 1) UTD (from Healthy Donor 2) UTD (from Healthy Donor 3) CNTY-101 & Autologous CAR-T on B Cells Isolated from Healthy Donors CNTY-101 & CAR-Ts from Healthy Donors on B Cells Isolated from SLE Patients CNTY-101 cells show similar potency to primary CAR-T cells in preclinical comparison CNTY-101 initial clinical data comparable to primary CAR-T cells at B-cell killing at 24 hours

27 CNTY-101: Systemic lupus erythematosus Phase 1 study 1 Standard lymphodepletion regimen: fludarabine (30 mg/m2/d) and cyclophosphamide IV (300 mg/m2/d) for 3 days Initial Dose Additional Cycle No lymphodepletion Schedule • Dose level 1: 300e6 • Dose level 2: 1000e6 LYMPHO-DEPLETION1 28-DAY DLT PERIOD RESPONSE ASSESSMENT Patient Enrollment Up to N=26 101 DAY 1 DAY 8 101 101 DAY 15 101 DAY 1 DAY 8 101 101 DAY 15 Inclusion: • Patients with moderate to severe SLE after 2+ standard immunosuppressive therapies RESPONSE ASSESSMENTs Months 2-12 Endpoints: • Key endpoints: safety, SLE manifestations per SLEDAI, LLDAS, DORIS • Translational Endpoints: B-cell depletion, auto-antibody decline Trial planned to initiate in the first half of 2024; initial data expected by year-end 2024

28 Product iPSC Platform Targets Indications Discovery Preclinical Clinical Collaborator P1 P2 P3 CNTY-101 iNK CD19 B-Cell Malignancies Systemic Lupus Erythematosus CNTY-102 iT CD19 + CD22 B-Cell Malignancies CNTY-107 iT Nectin-4 Solid Tumors Programs in Collaboration CNTY-104 iNK/iT Multi-specific Acute Myeloid Leukemia CNTY-106 iNK/iT Multi-specific Multiple Myeloma Research Programs Discovery iNK/iT TBD Hematological / Solid Tumors Solid Tumors Hematologic Tumors Autoimmune and Inflammatory Diseases Century Therapeutics pipeline of iPSC-derived allogeneic NK and T cell therapies

Closing

30 Century Therapeutics: Building an industry-leading, next-generation allogeneic iPSC-derived cell therapy platform LIMITLESS POTENTIAL... PRECISION DESIGN... ENDURING IMPACT... Foundational investments in iPSC technology, genetic editing, and manufacturing Progressing multiple clinical programs in oncology and autoimmune and inflammatory diseases Well-capitalized into 2026 to enable delivery on key milestones and clinical data

31 Q&A participants • Brent Pfeiffenberger, Pharm.D., Chief Executive Officer • Hy Levitsky, M.D., President of Research and Development • Nick Trede, M.D., Ph.D., SVP, Head of Clinical Development • Adrienne Farid, Ph.D., Chief Operations Officer and Head of Early Development • Michael Diem, M.D., Chief Financial Officer • Greg Russotti, Ph.D., Chief Technology and Manufacturing Officer

Initial Data from Phase 1 ELiPSE-1 Trial of CNTY-101 in Relapsed/Refractory B-cell Lymphomas and Overview of Planned Phase 1 Study in Systemic Lupus Erythematosus December 11, 2023